CVS Stock: Price, Earnings History and SEC Filings
CVS Health Corporation (CVS) last traded at $90.25, down 0.09% on the latest session and up 5.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $2.58 against an analyst estimate of $1.87, a beat of 38.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
CVS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $2.58 | $1.87 | +37.97% |
| Mar 2026 | May 6, 2026 | $2.57 | $2.21 | +16.29% |
| Dec 2025 | Feb 10, 2026 | $1.09 | $0.99 | +10.10% |
| Sep 2025 | Oct 29, 2025 | $1.60 | $1.36 | +17.65% |
CVS beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How CVS reacts to earnings
Across its last 8 earnings releases, CVS moved 5.7% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | Before open | -5.08% |
| 2026-05-06 | Before open | +7.65% |
| 2026-02-10 | Before open | -0.09% |
| 2025-10-29 | Before open | -1.95% |
| 2025-07-31 | Before open | -0.32% |
| 2025-05-01 | Before open | +4.11% |
| 2025-02-12 | Before open | +14.95% |
| 2024-11-06 | Before open | +11.33% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
CVS financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $402.1B | $1.8B | $7.8B | 0.4% | $1.39 |
| 2024 | $372.8B | $4.6B | $6.3B | 1.2% | $3.66 |
| 2023 | $357.8B | $8.3B | $10.4B | 2.3% | $6.47 |
| 2022 | $322.5B | $4.3B | $13.4B | 1.3% | $3.26 |
| 2021 | $292.1B | $8.0B | $15.7B | 2.7% | $6.02 |
| 2020 | $268.7B | $7.2B | $13.4B | 2.7% | $5.46 |
| 2019 | $256.8B | $6.6B | $10.4B | 2.6% | $5.08 |
| 2018 | $194.6B | -$594M | $6.8B | -0.3% | $-0.57 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for CVS
- 8-K · Aug 17, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · May 18, 2026Officer or director change, Shareholder vote
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 3, 2026
- 8-K · Mar 19, 2026Officer or director change
- 10-K · Feb 10, 2026
- 8-K · Feb 10, 2026Results of operations, Financial statements and exhibits
Insider filing activity
CVS insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
CVS news
- After He Returned From The Pacific Theater, A World War II Vet Bought $1,000 Of Walgreen Stock. 7 Decades Later, Russ Gremel’s $1,000 Investment Had Grown To Over $2 MillionNov 1, 2026 · 247wallst.com
- Mark Cuban Says Public Companies Found They Were ‘Ripped Off’ On Healthcare But Won’t Say So On Earnings CallsNov 1, 2026 · stocktwits.com
- CVS Health (CVS) Could Be 27% Undervalued As Earnings Focus SharpensOct 31, 2026 · finance.yahoo.com
- 1 value stock to own for decades and 2 we ignoreOct 30, 2026 · finance.yahoo.com
- BrightSpring Soars 12% on Q3 Beat and Raised 2026 Guidance as Adjusted EBITDA Jumps 42%Oct 30, 2026 · tikr.com
- CVS Health Stock: Analyst Estimates & RatingsOct 30, 2026 · barchart.com
- CVS Health: How Education and Everyday Action Can Support Medication SafetyOct 30, 2026 · finance.yahoo.com
- Countdown to CVS Health (CVS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPSOct 30, 2026 · finance.yahoo.com
About CVS Health Corporation
CVS Health Corporation (CVS) is a US-listed public company on NYSE. The SEC classifies its business as Retail-drug Stores and Proprietary Stores. It is incorporated in DE. Its fiscal year ends in December.